Original Article

Effects of continuous positive airway pressure on anxiety, depression, and major cardiac and cerebro-vascular events in obstructive sleep apnea patients with and without coronary artery disease

Ming-Chung Lee*, Yu-Chih Shen**, Ji-Hung Wang***, Yu-Ying Li**, Tzu-Hsien Li****, En-Ting Chang******, Hsiu-Mei Wang******

INTRODUCTION

Obstructive sleep apnea (OSA) is a type of sleep-disordered breathing that involves recurrent upper airway collapse leading to repetitive episodes of hypoxemia and arousal during sleep [1]. Cross-sectional and longitudinal studies have shown an association between OSA and hypertension [2,3], cardiovascular disease [4-6], and cerebrovascular events [7]. In patients with coronary artery disease (CAD), the prevalence of at least moderate OSA is approximately 50% [8-10], and OSA has been shown to be a significant predictor of incident CAD in males ≤70 years old after adjustment for other risk factors [4]. Therefore, OSA is an important comorbidity in patients with CAD.

Continuous positive airway pressure (CPAP) is the gold standard treatment for OSA. Treatment with CPAP has been shown to have positive effects on cardiovascular outcomes, including in studies conducted in patients with CAD [11-14]. However, the beneficial effects of treating OSA with CPAP in patients with CAD have not been confirmed in the recent studies [15-18].

OSA has also been linked with depression and anxiety, although the correlation between objective measures of OSA severity and subjective symptoms such as anxiety and depression is not

*Department of Human Development and Psychology, College of Humanities and Social Sciences, Tzu Chi University, Hualien, Taiwan, **Department of Psychiatry, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, ***School of Medicine, Tzu Chi University, Hualien, Taiwan, ****Department of Cardiology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan, *****Department of Psychiatry, Pingtung Branch of Kaohsiung Armed Forces General Hospital, Pingtung, Taiwan, ******Department of Chest, Buddhist Tzu Chi General Hospital, Hualien, Taiwan

© 2017 Tzu Chi Medical Journal | Published by Wolters Kluwer - Medknow
consistent [19-21]. There is also a reported link between depression and several aspects of heart disease [22]. In addition, CAD outcomes appear to be worse in the presence of anxiety and/or depression [22-24]. Treatment of OSA with CPAP has been shown to improve anxiety and depression symptoms [25,26]. However, less is known about the effects of CPAP treatment on anxiety and depression in patients with both OSA and CAD.

This study investigated the effects of CPAP therapy on anxiety and depression in patients with OSA alone or OSA plus CAD. The effects of CPAP on major adverse cardiac and cerebrovascular events (MACCE) over 1 year of follow-up in patients with OSA and CAD were also assessed.

**MATERIALS AND METHODS**

The study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committee of the institution (IRB 102-62). Informed written consent was obtained from all patients prior to their enrollment in this study.

**Participants**

This prospective study was conducted from 2010 to 2014 at Hualien Tzu-Chi General Hospital, Taiwan. Consecutive patients with moderate-to-severe OSA (apnea-hypopnea index ≥15/h) based on an overnight polysomnographic study (Embla A10, Embla, Broomfield, CO) at the sleep center, with or without a recent diagnosis of CAD (within the previous year), were eligible for the study. Patients <20 years old and those receiving treatment for anxiety and depression were excluded.

**Continuous positive airway pressure therapy and compliance**

All patients were started on CPAP treatment (S8; ResMed, San Diego, CA, USA) and underwent titration of therapy. CPAP compliance was defined as CPAP device usage for ≥4 h/night and use on ≥70% of days over 6 months of therapy and CPAP noncompliance was defined as CPAP device usage for <4 h/night and use on <70% of days over 6 months of therapy or refusal to use CPAP therapy. Data on CPAP usage were downloaded from the memory card in the CPAP machine with the agreement of all patients.

**Data collection and follow-up**

Baseline data collection included patient age, sex, body mass index, and daytime sleepiness (using the Epworth Sleep Scale [ESS] [27]). The presence of anxiety and depression was determined using Chinese versions of the Beck Anxiety Inventory (BAI) and Beck Depression Inventory-II (BDI-II), respectively, which have been shown to have moderate-to-strong validity and reliability [28,29]. Patients completed the BAI and BDI-II questionnaires at baseline and again at the 6-month follow-up.

All patients with OSA and CAD were assessed for the occurrence of MACCE; cardiac death, myocardial infarction, unplanned revascularization, and stroke. Follow-up was conducted via telephone every 3 months up to 1 year. MACCE was verified by the patient’s doctor and/or hospital medical records.

**Statistical analysis**

Analysis was performed using SPSS version 14.0 statistical package for Windows (SPSS, Chicago, IL, USA). Repeated-measures analysis of variance was used to compare scores on the ESS, BAI, and BDI-II at baseline and follow-up within each patient group. Statistical significance was set at P < 0.05. Kaplan–Meier analyses and Cox proportional hazards models were performed in the intention-to-treat population to estimate the impact of CPAP on the rate of MACCE.

**RESULTS**

**Patient characteristics**

A total of 79 patients were enrolled, of whom 43 patients had OSA only and 36 patients had both OSA and CAD. There were no statistically significant differences between the two patient groups with respect to patient data, polysomnographic findings, or anxiety and depression at baseline [Table 1].

**Continuous positive airway pressure compliance**

After 6 months’ follow-up, only 9 of the 36 patients with OSA and CAD were CPAP compliant; the remaining 27 of the 36 patients with OSA and CAD were CPAP noncompliant. For patients with OSA only 27 of 43 were CPAP compliant and 16 of 43 were CPAP noncompliant.

**Anxiety and depression**

Based on the BAI scores, there was a significant reduction in anxiety in CPAP-compliant OSA patients without CAD after 6 months of follow-up (P < 0.05), but not in CPAP-compliant OSA patients with CAD after 6 months of follow-up [Table 2]. Changes in the BAI from baseline to 6 months had a significantly larger effect size (ES) in CPAP-compliant OSA patients with CAD than in CPAP-compliant OSA patients without CAD (ES: 1.14) [Table 3]. The treatment difference and ES did not show differences in CPAP-compliant OSA patients without CAD (ES: 0.08) [Table 3].

Depression (assessed using the BDI-II score) also improved significantly from baseline to 6 months during CPAP treatment in CPAP-compliant OSA patients without CAD (P < 0.05), but not in CPAP-compliant OSA patients with CAD [Table 2]. As seen with anxiety, changes in the BDI-II score from baseline to 6 months had larger ESs in CPAP-compliant OSA patients with CAD than in CPAP-noncompliant OSA patients without CAD (ES: 1.22) and CPAP-compliant OSA patients without CAD (ES: 0.97) [Table 3].

**Major adverse cardiac and cerebrovascular events**

In OSA patients with CAD, good CPAP compliance was associated with a significant reduction in the incidence of MACCE after 1 year of follow-up (11% in CPAP-compliant and 50% in CPAP-noncompliant patients, P < 0.05) [Figure 1].

**DISCUSSION**

The results of this study showed that good compliance with CPAP decreased anxiety and depression in OSA patients without CAD. While improvements were not statistically significant in patients with OSA and CAD, the treatment difference in the ES showed significant reductions in the BAI and BDI-II scores after 6-month follow-up in CPAP-compliant patients. In addition, in patients with OSA and CAD, good CPAP compliance was found to significantly reduce the 1-year rate of MACCE compared with poor CPAP compliance or no CPAP use.
OSA is associated with sympathetic vasoconstriction along with simultaneous changes in intrathoracic and cardiac transmural pressures, which could contribute to the development of cardiac ischemia [17]. CPAP treatment of OSA is associated with reductions in desaturations, oxidative stress, sympathetic activity, inflammation, and possible myocardial ischemia during sleep [18]. Although a number of studies have reported beneficial effects of CPAP in patients with CAD [12-14], available evidence is far from consistent. Most recently, two large randomized controlled trials found no significant reduction in the rate of adverse cardiovascular outcomes during CPAP treatment in nonsleepy OSA patients with CAD (RICCADSA study) [17], or in those with coronary or cerebrovascular disease plus moderate-to-severe OSA and minimal sleepiness (SAVE trial) [18]. A nonrandomized longitudinal cohort study also found that CPAP treatment after an acute coronary syndrome event did not reduce the risk of a composite cardiovascular end point over a median follow-up of 75 months [16]. On-treatment analysis in the RICCADSA study suggested that higher levels of CPAP usage could significantly reduce cardiovascular risk, and patients who were adherent to CPAP therapy had a significantly lower risk of stroke compared with the non-CPAP group [17]. In our study, rates of MACCE in CPAP-compliant OSA patients with CAD were significantly reduced versus rates in CPAP-noncompliant OSA patients with CAD after 1 year of follow-up, but not after 6 months, suggesting that a longer follow-up might be required to detect any beneficial effects of CPAP on hard cardiovascular end points.

Anxiety and depression can affect patients with both OSA and CAD. It has been suggested that there is a link between OSA and psychological symptoms [19], and that psychosocial factors can influence the development of CAD and the occurrence of adverse cardiac events [22-24]. Previous neuroimaging data showed that nocturnal intermittent hypoxemia with OSA resulted in hippocampus atrophy and white matter changes that could possibly lead to cognitive and mood dysfunction [30]. However, the mechanism of CAD in anxiety and depression is still unknown. A recent systematic review and meta-analysis suggested that treatment of OSA with CPAP has a moderately positive effect on anxiety and depression [25]. Furthermore, the

---

**Table 1: Patient data at baseline**

|                  | OSA with CAD (n=36) | OSA without CAD (n=43) | P       |
|------------------|---------------------|------------------------|---------|
| Male, n (%)      | 32 (88.9)           | 35 (81.4)              | 0.531   |
| Age (years)      | 61.9±11.2           | 48.1±13.3              | 0.07    |
| BMI (kg/m²)      | 29.7±7.3            | 30.7±6.3               | 0.90    |
| ESS score        | 10.8±6.6            | 9.3±4.3                | 0.30    |
| Neck circumference (cm) | 39.2±5.7             | 39.9±3.1               | 0.22    |
| Sleep efficiency (%) | 79.2±14.2          | 79.1±10.1              | 0.13    |
| AHI (/h)         | 49.8±31.3           | 52.7±24.7              | 0.41    |
| ODI (/h)         | 39.6±31.4           | 37.4±29.8              | 0.81    |
| BAI score        | 11.8±10.3           | 3.1±9.0                | 0.83    |
| BDI-II score     | 11.6±9.8            | 9.9±9.9                | 0.77    |

Data are shown as mean±SD, or number of patients (%). OSA: Obstructive sleep apnea, CAD: Coronary artery disease, AHI: Apnea-hypopnea index, BAI: Beck Anxiety Inventory, BDI-II: Beck Depression Inventory version 2, BMI: Body mass index, ESS: Epworth Sleepiness Scale, ODI: Oxygen desaturation index, SD: Standard deviation.

**Table 2: Beck Anxiety Inventory and Beck Depression Inventory-II scores before and after the 6-month follow-up**

|                     | OSA with CAD | OSA without CAD |
|---------------------|--------------|-----------------|
|                     | CPAP (+)     | CPAP (−)        |
|                     | (n=9)        | (n=27)          |
|                     | CPAP (+)     | CPAP (−)        |
|                     | (n=27)       | (n=16)          |
| BAI score           |              |                 |
| Baseline            | 20.7±14.9    | 9.7±7.8         |
| 6-month follow-up   | 16.1±14.5    | 10.8±9.3        |
|                     | 5.4±6.9*     | 5.8±7.1         |
| BDI-II score        |              |                 |
| Baseline            | 20.4±14.3    | 9.5±7.2         |
| 6-month follow-up   | 15.9±7.3     | 10.8±8.5        |
|                     | 6.6±9.5*     | 6.8±9.5         |

*P<0.05 versus baseline. Values are presented as mean±SD. OSA: Obstructive sleep apnea, CPAP: Continuous positive airway pressure, CPAP (+): CPAP-compliant over 6 months’ follow-up, CPAP (−): CPAP-noncompliant over 6 months’ follow-up, OSA: Obstructive sleep apnea, BAI: Beck Anxiety Inventory, BDI: Beck Depression Inventory, SD: Standard deviation.

**Table 3: Comparison of treatment differences and effect sizes of 6-month treatment with continuous positive airway pressure in obstructive sleep apnea patients with or without coronary artery disease between continuous positive airway pressure-compliant and continuous positive airway pressure-noncompliant groups**

| Groups         | A-B       | C-D       |
|----------------|-----------|-----------|
| BAI score      | 9.9±3.7*  | −0.5±2.5  |
| ES             | 1.14      | 0.08      |
| BDI score      | 13.7±3.8* | 8.0±2.8*  |
| ES             | 1.22      | 0.97      |

*A-B significantly comparing with C-D, P<0.05. A-B significantly comparing with C-D, P<0.05. Group A: OSA with CAD, CPAP compliant over 6 months, Group B: OSA with CAD, CPAP noncompliant over 6 months, Group C: OSA without CAD, CPAP compliant over 6 months, Group D: OSA without CAD, CPAP noncompliant over 6 months, ES: Effect size, CPAP: Continuous positive airway pressure, BAI: Beck Anxiety Inventory, BDI: Beck Depression Inventory, SD: Standard deviation, OSA: Obstructive sleep apnea, CAD: Coronary artery disease.

---

![Risk function](image-url)
SAVE study in patients with OSA and CAD documented significant reductions in anxiety and depression in patients treated with CPAP compared with usual care [18]. In our study, CAD seemed to add to the severity of anxiety and depression in those with pure OSA. On the other hand, CPAP can decrease significant ES of CPAP in anxiety and depression in those with OSA/ CAD, rather than only depression showed more ES of CPAP used in pure compliant OSA. The beneficial effects of CPAP on mood were greater in both OSA and OSA/CAD patients with good CPAP compliance compared with poor compliance or no CPAP. However, low compliance and unwillingness to use CPAP were seen in more of our OSA patients with CAD than without CAD (25% vs. 63%). When CPAP compliance was poor, we found greater reductions in anxiety over 6 months’ follow-up in patients with OSA than those with OSA and CAD [Table 2, BAI decreased 1.5 from baseline to the 6-month follow-up in OSA and increased 1.1 in OSA with CAD for noncompliance group]. The potential of CPAP to reduce anxiety and depression could be clinically significant given that high levels of anxiety and depression have been linked with an increased mortality risk in CAD patients [31]. To our knowledge, this is the first study to compare the effects of CAD on mood in OSA patients with long-term CPAP treatment.

Several limitations need to be taken into account when interpreting our study findings. First, the use of CPAP was based on clinical indications for each patient and there was no randomization to therapy or use of a sham CPAP control group, meaning that potential sources of bias were not controlled for. Second, patient numbers in each patient group were small, especially the number of OSA/CAD patients who had good compliance with CPAP therapy. This limited our ability to detect statistically significant between-group differences. On the other hand, compliance with CPAP was poorer in OSA/CAD patients than those with OSA alone that would also affect the benefits of CPAP. Furthermore, we did not have any information on whether the improvements in anxiety and depression seen during CPAP therapy had any impact on objective clinical outcomes in our patients. Larger randomized trials are needed to further assess the effects of CPAP on mood in patients with OSA and CAD and to determine the effects of any changes on long-term clinical outcomes.

**Conclusions**

We showed that good CPAP compliance reduced anxiety and depression in patients with OSA regardless of CAD. In addition, good CPAP compliance significantly decreased the 1-year rate of MACCE in OSA patients with CAD.

**Financial support and sponsorship**

The study was funded by Buddhist Tzu Chi General Hospital, Hualien, Taiwan (TCRD 103-10).

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 1993;328:1230-5.

2. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000;283:1829-36.

3. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000;342:1378-84.

4. Gottlieb DJ, Yenokyan G, Newman AB, O’Connor GT, Punjabi NM, Quan SF, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: The Sleep Heart Health Study. Circulation 2010;122:352-60.

5. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 2005;353:2034-41.

6. Young T, Finn L, Peppard PE, Szklö-Coxe M, Austin D, Nieto FJ, et al. Sleep disordered breathing and mortality: Eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008;31:1071-8.

7. Das AM, Khan M. Obstructive sleep apnea and stroke. Expert Rev Cardiovasc Ther 2010;10:525-35.

8. Andreas S. Nocturnal insights in chronic heart failure. Eur Heart J 1999;20:1140-1.

9. Mooe T, Olafsson BO, Stegmayr B, Eriksson P. Ischemic stroke. Impact of a recent myocardial infarction. Stroke 1999;30:997-1001.

10. Peker Y, Kracizh H, Hedner J, Löth S, Johansson A, Bende M. An independent association between obstructive sleep apnoea and coronary artery disease. Eur Respir J 1999;14:179-84.

11. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: An observational study. Lancet 2005;365:1046-53.

12. Milleron O, Pillière R, Foucher A, de Roquefeuil F, Aegerter P, Jondeau G, et al. Benefits of obstructive sleep apnoea treatment in coronary artery disease: A long-term follow-up study. Eur Heart J 2004;25:728-34.

13. Buchner NJ, Samner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med 2007;176:1274-80.

14. Cassar A, Morgenthaler T, Lemmon RJ, Rihal CS, Lerman A. Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention. J Am Coll Cardiol 2007;50:1310-4.

15. Leão S, Conde B, Fontes P, Calvo T, Afonso A, Moreira I. Effect of obstructive sleep apnoea in acute coronary syndrome. Am J Cardiol 2016;117:1084-7.

16. Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea. The RICCADSA randomized controlled trial. Am J Respir Crit Care Med 2016;194:613-20.

17. Peker Y, Hedner J, Norum J, Durnaz T, Turhan S, Bozkurt E, et al. Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: A 7-year follow-up. Am J Respir Crit Care Med 2002;166:159-65.

18. McEvoy RD, Antic NA, Hickey E, Luo Y, Ou Q, Zhang X, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med 2016;375:919-31.

19. Macey PM, Woo MA, Kumar R, Cross RL, Harper RM. Relationship between obstructive sleep apnea severity and sleep, depression and anxiety symptoms in newly-diagnosed patients. PLoS One 2010;5:e10211.

20. Saunamäki T, Jehkonen M. Depression and anxiety in obstructive sleep apnea syndrome: A review. Acta Neurol Scand 2007;116:277-88.

21. Andrews JG, Oei TP. The roles of depression and anxiety in the understanding and treatment of obstructive sleep apnea syndrome. Clin Psychol Rev 2004;24:1031-49.
22. Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002;26:941-62.

23. Januzzi JL Jr., Stern TA, Pasternak RC, De Sanctis RW. The influence of anxiety and depression on outcomes of patients with coronary artery disease. Arch Intern Med 2000;160:1913-21.

24. Frasure-Smith N, Lespérance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry 2008;65:62-71.

25. Gupta MA, Simpson FC, Lyons DC. The effect of treating obstructive sleep apnea with positive airway pressure on depression and other subjective symptoms: A systematic review and meta-analysis. Sleep Med Rev 2016;28:55-68.

26. Sánchez AI, Martínez P, Miró E, Bardwell WA, Buela-Casal G. CPAP and behavioral therapies in patients with obstructive sleep apnea: Effects on daytime sleepiness, mood, and cognitive function. Sleep Med Rev 2009;13:223-33.

27. Chen NH, Johns MW, Li HY, Chu CC, Liang SC, Shu YH, et al. Validation of a Chinese version of the Epworth Sleepiness Scale. Qual Life Res 2002;11:817-21.

28. Zheng YP, Wei LA, Goa LG, Zhang GC, Wong CG. Applicability of the Chinese Beck depression inventory. Compr Psychiatry 1988;29:484-9.

29. Cheng K, Wong C, Wong K. A study of psychometric properties, normative scores and factor structure of Beck Anxiety Inventory Chinese version. Chin J Clin Psychol 2002;1:4-6.

30. Zimmerman ME, Aloia MS. A review of neuroimaging in obstructive sleep apnea. J Clin Sleep Med 2006;2:461-71.

31. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J 2015;170:1105-15.